Finvest
MDGL Biotechnology · Commercial biotech · NASH · Single product · Thesis updated July 12, 2026

Rezdiffra works, but spending is the fight

01 Running thesis

A blockbuster with a burn rate

Madrigal has done the hard part that many biotechs never reach. It launched Rezdiffra and created large demand in a new drug market. Q1 2026 net sales were $311.3M, up 127% from a year earlier. Management also said Rezdiffra produced more than $1.1B in net sales over the last 12 months.

The bull case is simple. Rezdiffra is first in a large disease area, NASH, now often called MASH. The drug treats patients with moderate to advanced liver scarring before cirrhosis. Madrigal also raised its estimate of U.S. patients under specialist care to about 460,000, which makes the long-term market look bigger than before.

The bear case is also simple. Madrigal is spending heavily to build the market and defend its lead. Q1 2026 net loss widened to $94.4M. SG&A rose 60%, helped by direct-to-consumer marketing and a larger commercial push. R&D rose 146%, including $54.3M of one-time upfront payments for pipeline deals.

The key tension is no longer whether Rezdiffra can sell. It can. The open question is how much cash Madrigal must spend before sales growth, payer discounts, and operating costs line up into steady profits.

May 2026→Q1 2026 showed both sides of the story. Rezdiffra net sales reached $311.3M, up 127% year over year, but the net loss widened to $94.4M as SG&A and R&D spending jumped.
Feb 2026→Full-year 2025 Rezdiffra sales reached $958M, proving the launch was strong. The view stayed balanced because heavy SG&A and R&D spending pushed the profit timeline out.
Aug 2025▲Q2 2025 sales rose 55% quarter over quarter to $213M, and patient growth kept building. A new U.S. patent extending protection to February 2045 made the long-term Rezdiffra franchise more valuable.
May 2025▲Q1 2025 net revenue of $137.3M beat expectations and rose 33% from Q4 2024. Treated patients passed 17,000, which strengthened confidence in the launch.
Feb 2025▲Q4 2024 net sales reached $103M, up 66% quarter over quarter. Patients on Rezdiffra rose to more than 11,800, and the F4 cirrhosis opportunity became a bigger part of the upside case.
Oct 2024▲Q3 2024 net sales of $62M and more than 6,800 patients showed the launch was moving faster than expected. Madrigal also reached its 80% commercial coverage goal early.
Aug 2024▲The first full commercial quarter set the starting thesis. Rezdiffra generated $14.6M in net sales and ended the quarter with more than 2,000 patients, showing early demand in a new market.
02 Business model

Selling through liver specialists

Madrigal makes money from one product: Rezdiffra. It sells the drug in the U.S. through a limited specialty pharmacy network. The main prescribers are hepatologists and gastroenterologists, doctors who treat liver and digestive diseases.

This is a first-in-disease launch. That means Madrigal must teach doctors how to find the right patients, help offices process prescriptions, and work with payers on coverage. That work can create a strong early lead, but it costs a lot.

The moat has improved. Madrigal has a U.S. patent on Rezdiffra's commercial weight-based dosing regimen that expires in February 2045. If that patent holds up, it extends the drug's protected life from a normal launch window into a much longer franchise.

The next layer is geography. All current revenue is from the U.S. Madrigal plans to sell directly in Europe after an expected EMA decision, starting with Germany. That could add growth, but it also adds launch cost and reimbursement risk in each country.

03 Product portfolio

One drug, many follow-ons

Growth engine

Rezdiffra

Rezdiffra is the only commercial product and the whole revenue base today. It is approved for noncirrhotic NASH with moderate to advanced liver fibrosis.

Option

F4 cirrhosis expansion

Madrigal is testing Rezdiffra in compensated NASH cirrhosis, called F4 disease. A pivotal outcomes trial is expected to read out in 2027 and could expand the addressable market.

Option

MGL-2086

MGL-2086 is Madrigal's oral GLP-1 program. It entered Phase 1 in 2026 and is meant to support future combination treatment with Rezdiffra.

Option

Ervogastat

Ervogastat is a DGAT2 inhibitor brought in to build combination therapy options. Madrigal has discussed Phase 2 combination work with Rezdiffra.

Option

ARO-PNPLA3

ARO-PNPLA3 is an siRNA program, a drug approach that aims to silence a disease-related gene. It adds another mechanism to Madrigal's NASH pipeline.

04 Business segments

U.S. sales for now

U.S. Rezdiffra100%growing fast
Europe direct launch0%flat

For Q1 2026, Madrigal reported $311.3M of product revenue and the internal segment view treats all current revenue as U.S. Rezdiffra sales. Europe is included as a zero-revenue launch option because Madrigal plans a direct launch after an EMA decision.

05 Risk factors

What could break the thesis

Launch growth slows

High impact · Medium odds

Rezdiffra sales are already large, but Q1 2026 sales were slightly below Q4 2025. That may be normal quarter noise, seasonal effects, or gross-to-net timing. If it marks real slowing, the stock story changes fast because the company is still built around one product.

We watchQuarterly Rezdiffra net sales, active patient count, and prescriber growth.

Gross-to-net pressure

High impact · Medium odds

Gross-to-net means the gap between list-price sales and what Madrigal keeps after rebates, discounts, and fees. Management expects this discount to be in the mid-to-high 30% range for the rest of 2026. If the discount rises above that, profit becomes harder even if prescriptions grow.

We watchReported gross-to-net discount range and any payer coverage changes.

Market-building costs stay too high

High impact · High odds

Madrigal is paying to create the NASH treatment market. Q1 2026 SG&A rose 60%, driven by commercial work, direct-to-consumer marketing, and compensation costs. If the company needs this level of spending for years, the path to sustained profit gets pushed out.

We watchSG&A dollars, sales force comments, DTC spending, and management's profit timing.

Pipeline bets disappoint

Medium impact · Medium odds

Madrigal is using Rezdiffra cash flow to build a broad NASH pipeline. Q1 2026 R&D rose 146%, including $54.3M of one-time upfront payments for business development. If MGL-2086, ervogastat, or ARO-PNPLA3 fail, the company may have spent heavily without extending its lead.

We watchPhase 1 updates for MGL-2086 and timing for Phase 2 combination studies.

Future competition changes the market

High impact · Medium odds

NASH is a large market, so other drug makers will keep trying. GLP-1 drugs and other mechanisms could take share or pressure pricing over time. Madrigal's own oral GLP-1 strategy is meant to reduce this risk, but it is still early.

We watchCompetitor trial readouts, new approvals in NASH, and GLP-1 combination data.
06 Quick answers

In one breath

What does Madrigal Pharmaceuticals do?

Madrigal sells Rezdiffra, a drug for certain NASH patients with moderate to advanced liver scarring. It is also building a pipeline of follow-on and combination treatments in the same disease area.

Why is Rezdiffra important?

Rezdiffra was the first approved drug for its target NASH population. That gives Madrigal a first-mover lead with doctors, payers, and specialty pharmacies.

Is Madrigal profitable?

No, not as of Q1 2026. The company reported a $94.4M net loss as it spent heavily on marketing, sales, and pipeline deals.

What is the next big catalyst for MDGL?

The next 12 months center on Rezdiffra sales growth, patient metrics, the EMA decision and Germany launch plan, and early updates from MGL-2086. The F4 cirrhosis outcomes trial is expected to read out in 2027.